NL-OMON40194已完成2 期
Sandostatin therapy in sarcoidosis - SST in SA
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Age above 18 years with obtained written consent
- •* Have biopsy-proven symptomatic, stable, chronic sarcoidosis for minimal three years.
- •* Have a positive SRS
- •* Involvement of skin, joint, lymph nodes or lung. Patients with pulmonary involvement have a diffusing capacity between 60 and 75 percent.
排除标准
- •* Corticosteroid use up to three months prior of trial
- •* Chronic renal failure defined as a GFR below 50%
- •* Liver disease
- •* Have an indication for intensifying immunosuppressive therapy; threatening organ damage
- •* Have failed on earlier anti TNF-* therapy
- •* Have an underlying cardiac disease
研究者
相似试验
进行中（未招募）
不适用
Sandostatin therapy in sarcoidosisSarcoidosisEUCTR2013-005376-17-NLErasmus Medical Center
招募中
不适用
Sandostatin therapy in sarcoidosisSarcoidosis, sandostatinSarcoïdose, sandostatineNL-OMON25865Erasmus Medical Center, Department of Internal Medicine.20
进行中（未招募）
1 期
Trial for patients with neuro-endocrine tumors with carcinoid syndrome receiving octreotide LAR.The primary objective is to observe the change from baseline in the incidence of diarrhea and flushing in correlation to the serum octreotide level, independently of the dose variations of octreotide LAR.EUCTR2014-003856-30-BECliniques Universitaires Saint Luc50
已完成
2 期
Azithromycin a Treatment for Pulmonary SarcoidosisSarcoidosis, PulmonaryNCT04020380Hull University Teaching Hospitals NHS Trust21
已完成
3 期
Efficacy and Safety of Influenza Vaccine During SarcoidosisInfluenza VaccineSarcoidosisNCT01687517Assistance Publique - Hôpitaux de Paris190